Hepatitis B virus subviral particle assembly and secretion machinery (HBV SVP machinery)

The Hepatitis B virus (HBV) subviral particle (SVP) assembly and secretion machinery is a critical component of the HBV life cycle responsible for the production of non-infectious particles composed of HBV surface antigens (HBsAg) (PubMed: 27118357). These SVPs are produced in vast excess, often 1,000 to 100,000-fold more than infectious virions, and serve as immunological decoys that exhaust the host's immune response, preventing the clearance of the virus (NCBI: NBK470413). The machinery involves the synthesis of Large, Medium, and Small HBsAg proteins in the endoplasmic reticulum and their subsequent assembly into spherical or filamentous particles for secretion via the host's constitutive secretory pathway (Journal of Hepatology, 2020). Targeting this machinery is a major therapeutic strategy aimed at achieving a "functional cure" for chronic hepatitis B. By inhibiting the release of SVPs, drugs like nucleic acid polymers (NAPs), such as REP 2139, can dramatically reduce circulating HBsAg levels, which in turn allows the host immune system to recover and potentially achieve HBsAg seroconversion (Replicor Inc., 2023). This approach is often combined with other antivirals, such as pegylated interferon or nucleos(t)ide analogs, to maximize the chances of long-term viral suppression and immune control.

Other names

HBsAg secretion pathwayHBV subviral particle pathwaySubviral particle assembly complexHBsAg release machinery

Inhibition of the assembly and release of non-infectious subviral particles (SVPs) from hepatocytes, primarily by targeting the interaction of viral surface antigens with host secretory pathways, thereby reducing circulating HBsAg levels and relieving HBsAg-mediated immune suppression.